Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Innovative Industrial Properties

NextEra Energy

Procter & Gamble

Sirius XM Holdings Inc

AT&T

Visa

Some businesses actually perform quite well when a recession strikes.

7 of the Most Recession-Resistant Stocks to Buy Now

Amazon

FedEx

Falling share prices have created some very appealing buying opportunities for investors today.

3 Stocks to Buy in The Coronavirus-Fueled Market Crash

Johnson & Johnson is seeing a spike in demand for its Tylenol over-the-counter pain killer and other self-care products, the company said on Friday, as the global spread of the coronavirus prompts people to stock up on essentials.

Tylenol sales surge on coronavirus concerns

F5 Networks

Intuitive Surgical

Microsoft

Regeneron Pharmaceuticals

Jeff Reeves lists stocks that should be relatively safe as business conditions threaten some companies with bankruptcy

Jeff Reeves's Strength in Numbers: These are the five most financially sound companies amid a cash crunch

Walmart

With the markets making big moves in both directions, it's time to consider the best volatility-resistant stocks to buy.

3 Stocks to Buy That Will Dodge Any Volatile Market

Going by the trends seen during the 2008 economic slowdown, it’s likely that Johnson & Johnson (NYSE: JNJ) stock could bounce back strongly, but it may not outperform the broader market on the way up, as the coronavirus crisis winds down. S&P fell over 2x compared to Johnson & Johnson’s stock.

Can Johnson & Johnson’s Stock Outperform S&P 500 When Coronavirus Crisis Winds Down?

Bank of America

Buying great businesses at a fair price is a recipe for long-term wealth creation.

5 Stocks Smart Investors Are Buying Right Now

Cocrystal Pharma

Gilead Sciences

GlaxoSmithKline

Inovio Pharmaceuticals

Moderna

NanoViricides

Novavax

Pfizer

Sanofi

Vaxart

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

The drug combination has to be injected, but only having to deal with treatment once a month could be worth it for many patients.

Pfizer, GlaxoSmithKline, Johnson & Johnson Team Up on Once-Monthly HIV Treatment

The head of the World Health Organization describes the threat of the coronavirus outbreak reaching pandemic proportions as "very real."

COVID-19 Nearing Pandemic Level, WHO Warns

Duke Energy

Kroger

Teva Pharmaceutical

Hostess Brands

Waste Management

As the coronavirus pandemic worsens, stable but boring recession-proof stocks to buy are suddenly in vogue. Here are the nine picks that might ride this black swan even to profitability.

9 Recession-Proof Stocks to Disinfect the Coronavirus

7 Big Pharma Companies Trump Asked to Fight the Coronavirus Outbreak

Apple

Alphabet

JPMorgan Chase & Co

The bloodbath that created the major panic selling on Monday, March 9, 2020 was caused by a double-whammy of the continued spreading of the coronavirus outbreak coinciding with a fresh all-out oil price war between Russia and Saudi Arabia.

Putting the Massive Losses in America’s 10 Largest Companies in Context

AIM ImmunoTech Inc

Vir Biotechnology

Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.

Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …

Morgan Stanley

ESG investment has carved a niche in stock markets and millennials are the ones driving its rapid growth.

Millennials Are Inclined Toward ESG: Here's Why

Johnson & Johnson: A Steadily Growing Dividend Compounder, Buy Low On Coronavirus Fears

AbbVie

Takeda Pharmaceutical

Not yet, but multiple drugmakers are working on treatments and vaccines.

Is There a Cure for the SARS-CoV-2 Coronavirus?

JNJ stock topped a buy point. But several lawsuits claiming Johnson & Johnson baby powder caused cancer are weighing on shares.

Is JNJ Stock A Buy As It Wages Battle Against The New Coronavirus?

Johnson & Johnson (NYSE: JNJ) revenue grew at a CAGR of 4.1% from $70.0 billion in 2015 to $82.0 billion in 2019, and it is estimated to top $85 billion in 2020, led by its pharmaceuticals business, which is expected to be the single-biggest revenue driver with $44.8 billion in revenues.

How JNJ Gets To $85 Billion: Devices, Pharma, or Consumer?

Johnson & Johnson (JNJ) closed the most recent trading day at $142.01, moving -1.02% from the previous trading session.

Johnson & Johnson (JNJ) Stock Moves -1.02%: What You Should Know

Waste Connections

If you fear a looming recession, these three stocks should help your portfolio weather the storm.

News for Johnson & Johnson Stock (JNJ)